Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for CRVO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 22.96M
March 31, 2026 10.62M
December 31, 2025 18.22M
September 30, 2025 26.01M
June 30, 2025 33.44M
March 31, 2025 34.63M
December 31, 2024 39.20M
September 30, 2024 45.64M
June 30, 2024 49.98M
March 31, 2024 5.336M
December 31, 2023 7.377M
September 30, 2023 9.574M
June 30, 2023 14.23M
March 31, 2023 16.28M
December 31, 2022 -33.29M
September 30, 2022 24.05M
June 30, 2022 26.67M
March 31, 2022 30.62M
December 31, 2021 34.91M
September 30, 2021 38.13M
June 30, 2021 50.17M
March 31, 2021 53.65M
December 31, 2020 24.81M
September 30, 2020 28.72M
June 30, 2020 32.88M
Date Value
March 31, 2020 17.90M
December 31, 2019 20.13M
September 30, 2019 13.52M
June 30, 2019 16.18M
March 31, 2019 12.96M
December 31, 2018 15.61M
September 30, 2018 20.91M
June 30, 2018 27.30M
March 31, 2018 29.72M
December 31, 2017 21.23M
September 30, 2017 6.357M
June 30, 2017 1.168M
March 31, 2017 -19.12M
December 31, 2016 9.185M
September 30, 2016 11.49M
June 30, 2016 14.03M
March 31, 2016 16.58M
December 31, 2015 16.44M
September 30, 2015 19.07M
June 30, 2015 31.81M
March 31, 2015 35.25M
December 31, 2014 38.17M
September 30, 2014 42.80M
June 30, 2014 45.30M
March 31, 2014 12.21M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics